Pharmaceuticals

National University Health System Launches World's First Public Hospital's Healthy Longevity Clinic at Alexandra Hospital

SINGAPORE, Sept. 2, 2023 /PRNewswire/ -- The National University Health System (NUHS), NUS Yong Loo Lin School of Medicine andAlexandra Hospital (AH ) have achieved a milestone by unveiling the world's inaugural Healthy Longevity Clinic by public healthcare. Located atSing...

2023-09-02 13:00 4238

Sirnaomics Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors

* Six cohorts, totaling 50 late-stage cancer patients, received STP707 four times monthly by intravenous infusion at escalating dosages. * All cohorts demonstrated a strong safety profile with no dose-limiting toxicity noted for any dosing cohort and the treated patients exhibited encouraging...

2023-08-31 11:30 5584

Sirnaomics Announces 2023 Interim Results

Positive Clinical Readouts Validate Potential of Proprietary Delivery Platforms and Cement Global Leadership in RNAi Therapeutics Business Highlights Promising progress in clinical development * After an End of Phase-II meeting and with guidance from the U.S. FDA, the Group is advancing the l...

2023-08-31 10:40 5203

The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare

* Japanese Ministry of Health, Labor and Welfare grants Orphan Drug Designation to tagraxofusp for blastic plasmacytoid dendritic cell neoplasm (BPDCN) FLORENCE, Italy and NEW YORK, Aug. 30, 2023 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagno...

2023-08-30 23:15 2833

European Society of Cardiology Congress: Traditional Chinese Medicine Qili Qiangxin significantly reduces the risk of cardiovascular death and re-hospitalization due to heart failure

AMSTERDAM, Aug. 30, 2023 /PRNewswire/ -- The latest study indicates that adding TCM Qili Qiangxin Capsules (developed and produced by Yiling Pharmaceutical) to the standard of care for heart failure can significantly reduce the risk of re-hospitalization due to worsening heart failure and cardio...

2023-08-30 20:11 2628

Igniting Innovation, Catalyzing Changes: Bio Farma x MIT Hacking Medicine Hackathon Celebrates Success

JAKARTA, Indonesia, Aug. 30, 2023 /PRNewswire/ -- Bio Farma , Indonesia's state-owned pharmaceutical company, has successfully concluded theBio Farma x MIT Hacking Medicine on August 24 to 27, 2023 in Bali. Over the course of four days, the Hackathon oversaw 200 chos...

2023-08-30 16:16 2482

Cerecin to Present New Infantile Spasms Data at the 35th International Epilepsy Congress, Dublin 2023

* Data from the pilot study in infantile spasms showed positive outcomes. * The results will be presented by Cerecin's Chief Medical Officer, Dr. Marc Cantillon on Sunday 2nd September at 2pm (GMT+1). * The Cerecin team will be accompanied by PharmaVentures, who will be supporting Cerecin's ...

2023-08-30 00:04 2110

Viva Biotech (1873.HK) Announces 2023 Interim Results:Solid Growth in Main Business, Significant Rebound in Profitability

Highlights of the Interim Results as of June 30, 2023: * Revenue reached RMB1,142.2 million, representing a year-on-year increase of approximately 3.0% * Gross profit amounted to RMB406.0 million, representing a year-on-year increase of approximately 17.7% * Adjusted Non-IFRS net profit amo...

2023-08-29 22:38 3178

Bayer Launches Stunting Prevention Program "CETING" for Community of Cisalak, Depok

DEPOK, Indonesia, Aug. 29, 2023 /PRNewswire/ -- Bayer, a global Life Science company in health and nutrition, is taking an active role in addressing the stunting problem inIndonesia. Coinciding with Bayer's 66th year in Indonesia, Bayer launched the CETING (Prevent Stunting) program for the commu...

2023-08-29 13:53 2774

Ferinject® granted upgraded recommendations in 2023 ESC heart failure guidelines

The 2023 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) include upgraded recommendations for intravenous (IV) iron supplementation, including Ferinject® (ferric carboxymaltose), for the management of iron deficiency in patients with HF. Phase IV HEART-FI...

2023-08-28 19:00 2910

Jiangsu Recbio Technology Co., Ltd. announced 2023 interim results report and latest progress

TAIZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and interim results for 2023. During the reporting period, the company always adhered to the mission of " Protect Human Health With Best-In-Class Vaccines", rapidly promoted pr...

2023-08-28 11:08 3947

Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline

SHANGHAI and HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), today announced its interim results for the six-months endedJune 30, 2023, and provided updates on multiple milestones achieved since the beginning of 2023. Dr. Jay Mei, Antengene's F...

2023-08-25 19:37 2867

Henlius 2023 H1 Results: Achieved record profits and RMB2.5 billion revenues, opening a new chapter of high-quality growth

SHANGHAI, Aug. 25, 2023 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 interim results. In the first half of 2023, Henlius reported a boost in operating profits ofRMB240.0 million and revenues of RMB2.5005 billion, up by 93.9% YoY, driven by growth in core oncology products. HANQUYOU (trast...

2023-08-25 19:26 6527

3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced

HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximatelyRMB3,783.8 million, up 22.3% on a yearly basis. Gross profit was approximatelyRMB3,201.6 million, up ...

2023-08-25 10:06 5446

Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon® for the Treatment of Primary IgA Nephropathy

SHANGHAI, Aug. 25, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Ph...

2023-08-25 08:15 3043

Antheia Achieves Major Commercial Milestone

Company's first full-scale fermentation run reinforces commercial viability for a robust pipeline of Biosynthetic KSMs and APIs MENLO PARK, Calif., Aug. 25, 2023 /PRNewswire/ -- Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the...

2023-08-25 08:01 2774

YS Biopharma Announces Purchase of Shares by Company Officers

GAITHERSBURG, Md., Aug. 25, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2023-08-25 04:15 2799

Everest Medicines Announces Interim Results for First Half of 2023

SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2023, ...

2023-08-24 08:15 6330

Innovent Announces 2023 Interim Results and Business Updates

Remarkable achievements with accelerated growth and improved efficiency to underpin sustainable growth ROCKVILLE, M.D. and SUZHOU, China, Aug. 23, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and comme...

2023-08-23 19:38 5609

Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company

MELBOURNE, Australia, Aug. 23, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended30 June 2023. All figures are in AUD$ unless otherwise stated.[1] Financial highlights * Total Group revenue $220.8M ...

2023-08-23 17:40 2026
1 ... 78798081828384 ... 186

Week's Top Stories